Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
30
2
4
5
6
8
9
10
11
12
13
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
World Congress on Medical Toxicology
2020-12-01 - 2020-12-02    
12:00 am
World Congress on Medical Toxicology Medical Toxicology Pharma 2020 provides a global platform to meet and develop interpersonal relationship with the world’s leading toxicologists, pharmacologists, [...]
01 Dec
2020-12-01 - 2020-12-02    
All Day
International Conference on Food Technology & Beverages” at Kyoto, Japan in the course of Kyoto, Japan, December, 01-02, 2020 Theme of the Food Tech 2020 [...]
Biomedical, Bio Pharma and Clinical Research
2020-12-03 - 2020-12-04    
12:00 am
Biomedical, Bio Pharma and Clinical Research Conference Series LLC LTD cordially invites you to be a part of “2nd International Conference on Biomedical, Bio Pharma [...]
NODE Health 4th Annual Digital Medicine Conference
2020-12-07 - 2020-12-12    
12:00 am
NODE.Health is delighted to announce the 4th Annual Digital Medicine Conference - Evidence Matters. Never before has the transformation of our healthcare system been more [...]
2020 Global Digital Health Forum
2020-12-07 - 2020-12-09    
12:00 am
Organized by Global Digital Health Network Digital health can be the great leveler – it can give anyone access to information about health and disease. [...]
International Conference on Cancer Treatment and Prevention
2020-12-14 - 2020-12-15    
12:00 am
Cancer Treatment Forum 2020 regards each one of the individuals to go to the "Cancer Treatment Forum 2020" amidst December 15, 2020 UK-Time Zone( GMT [...]
International Conference on Neurology and Neural Disorders
2020-12-14 - 2020-12-15    
12:00 am
International Conference on Neurology and Neural Disorders Neurology Research 2020 will join world-class professors, scientists, researchers, students, perfusionist, neurologist to discuss methodology for ailment remediation [...]
Events on 2020-12-03
Latest News

Keep Emerson (EMR) in Your Portfolio: Here’s Why

Emerson Electric Co is experiencing robust demand across multiple sectors, especially in process and hybrid markets, which is propelling its order growth. Management foresees sustained strong sales in these markets throughout fiscal 2024, driven by the resilience of chemical, life sciences, LNG, metals and mining, and sustainability and decarbonization sectors.

In the Intelligent Devices segment, Emerson is observing strong performance in measurement and analytical, as well as final control businesses, supported by demand in hybrid and process markets. With optimism prevailing across its segments, Emerson anticipates a 12.5-14.5% surge in net sales for the second quarter of fiscal 2024 compared to the prior year.

Emerson is actively pursuing expansion through acquisitions. Recent acquisitions such as Afag and Flexim have bolstered its capabilities in factory automation, battery manufacturing, automotive, electronics, and automation portfolio. Additionally, the acquisition of National Instruments has strengthened its footprint in semiconductor, electronics, transportation, electric vehicles, and aerospace & defense sectors.

The company is committed to enhancing shareholder value through dividends and share repurchases. In the first quarter of fiscal 2024, it disbursed dividends totaling $300 million and repurchased common stocks worth $175 million. Furthermore, Emerson raised its dividend by 1% in October 2023.
User

However, EMR has noted a decline in performance within its test and measurement business segment under the Software and Control division. In the initial fiscal quarter, orders for this sector dropped by 17% compared to the preceding year, attributed to sustained softness in discrete and semiconductor markets, alongside continued challenges in China.

The company’s profitability has been impacted by escalating operational costs and expenditures. For example, in the first fiscal quarter, its cost of sales experienced a significant increase of 25.6% year over year, while selling, general, and administrative expenses saw a rise of 24%. Consequently, the pre-tax margin for the quarter decreased to 3.4%, down from 12.5% in the corresponding fiscal quarter of the previous year.